8-K: Philip Morris International Reports Strong Q2, Raises Full-Year Guidance on Smoke-Free Momentum

Philip Morris International delivered very strong second-quarter and first-half 2025 financial results, driven by exceptional growth in its smoke-free business, leading to a raised full-year guidance.

Summary

• Second quarter 2025 reported diluted EPS grew 26.6% to $1.95, while adjusted diluted EPS grew 20.1% to $1.91, and by 18.9% excluding currency.
• First six months 2025 reported diluted EPS grew 25.7% to $3.67, while adjusted diluted EPS grew 16.1% to $3.60, and by 17.7% excluding currency.
• The smoke-free business (SFB) accounted for 41% of total net revenues and over 42% of total gross profit in Q2 2025.
• SFB shipment volumes increased by 11.8% in Q2, with net revenues growing 15.2% (14.5% organically) and gross profit increasing 23.3% (21.5% organically).
• IQOS exceeded $3 billion in quarterly net revenues and strengthened its position as the second largest nicotine brand in markets where present, gaining 1.0 percentage point of combined cigarette and HTU industry volumes to reach 9.2% share.
• Heated Tobacco Unit (HTU) adjusted in-market sales (IMS) volume reaccelerated to double-digit growth of 11.4%.
• In the U.S., ZYN reaccelerated its offtake growth to approximately 36% in June and 26% in Q2 overall, with shipment volumes growing over 40% to 190 million cans.
• VEEV e-vapor shipment volumes more than doubled, driven by Europe, and is now available in 42 markets.
• Combustible net revenues grew by 2.1% (2.0% organically) fueled by strong pricing, partly offset by negative mix dynamics, despite a 1.5% volume decline.
• Marlboro gained market share, achieving its highest quarterly market share since the 2008 spin.
• A regular quarterly dividend of $1.35 per share, or an annualized $5.40 per share, was declared.
• Full-year 2025 adjusted diluted EPS guidance was raised to a range of $7.43-$7.56, representing a projected increase of 13% to 15% versus 2024 adjusted diluted EPS of $6.57.

Sentiment

Score: 9

Explanation: The filing indicates very strong financial performance, particularly driven by the smoke-free business, and a positive outlook with raised full-year guidance, reflecting successful strategic execution and market leadership in key growth categories.

Positives

• Delivered very strong results in the second quarter, with record net revenues and exceptional growth in operating income and adjusted diluted EPS.
• Achieved excellent momentum in the multicategory smoke-free business, with reacceleration of IQOS adjusted in-market sales growth and ZYN U.S. offtake growth.
• Smoke-free business now accounts for 41% of total net revenues and over 42% of total gross profit, demonstrating successful portfolio transformation.
• IQOS exceeded $3 billion in quarterly net revenues, solidifying its position as a key growth driver.
• Marlboro achieved its highest quarterly market share since the 2008 spin, indicating continued strength in the combustible segment.
• Raised full-year 2025 guidance for adjusted diluted EPS, reflecting confidence in continued strong performance.
• Strong organic operating income growth of 14.9% in Q2 and 15.4% in H1, driven by favorable pricing and smoke-free product volume.

Negatives

• Combustible shipment volumes declined by 1.5% in Q2 and 0.3% in H1, reflecting an expected return to volume declines.
• Negative mix dynamics partly offset strong pricing in the combustible business.
• Cigarette shipment decreases were noted in several markets, including France (down 17.5%), Italy (down 4.1%), Poland (down 4.6%), Turkey (down 8.0% due to supply chain issues), and Indonesia (down 3.7%).
• Forecasted total international industry volume decline of around 1% for cigarettes and HTUs (excluding China and the U.S.) for the full year.
• Forecasted cigarette volume declines of around 2% for the full-year 2025.

Risks

• Excise tax increases and discriminatory tax structures.
• Increasing marketing and regulatory restrictions that could reduce competitiveness, eliminate the ability to communicate with adult consumers, or ban certain products.
• Health concerns relating to the use of tobacco and other nicotine-containing products and exposure to environmental tobacco smoke.
• Litigation related to tobacco and/or nicotine use and intellectual property.
• Intense competition.
• Effects of global and individual country economic, regulatory, and political developments, natural disasters, and conflicts.
• The impact and consequences of Russia's invasion of Ukraine.
• Changes in adult smoker behavior.
• The impact of natural disasters and pandemics on the business.
• Lost revenues as a result of counterfeiting, contraband, and cross-border purchases.
• Governmental investigations.
• Unfavorable currency exchange rates and currency devaluations, and limitations on the ability to repatriate funds.
• Adverse changes in applicable corporate tax laws.
• Recent and potential future tariffs imposed by the U.S. and other countries.
• Adverse changes in the cost, availability, and quality of tobacco and other agricultural products and raw materials, as well as components and materials for electronic devices.
• The integrity of information systems and effectiveness of data privacy policies.
• Unsuccessful attempts to introduce, commercialize, and grow smoke-free products or if regulation or taxation do not differentiate between such products and cigarettes.
• Inability to successfully introduce new products, promote brand equity, enter new markets, or improve margins through increased prices and productivity gains.
• Inability to expand the brand portfolio internally or through acquisitions and the development of strategic business relationships.
• Inability to attract and retain the best global talent, including women or diverse candidates.
• Inability to successfully integrate and realize the expected benefits from recent transactions and acquisitions.
• Lower predictability of smoke-free products performance.

Future Outlook

Philip Morris International raised its full-year 2025 guidance, forecasting reported diluted EPS between $7.24 and $7.37, and adjusted diluted EPS (excluding currency) to grow by 11.5% to 13.5% to a range of $7.33 to $7.46. The company expects total shipment volume growth of around 1%, driven by 12% to 14% smoke-free product volume growth, partly offset by an estimated 2% decline in cigarette volumes. Organic net revenue growth is projected at 6% to 8%, with organic operating income growth of 11% to 12.5%. Operating cash flow is anticipated to be approximately $11.5 billion, with capital expenditures around $1.6 billion, primarily supporting the smoke-free business. The company targets a net debt to adjusted EBITDA ratio of around 2x by the end of 2026 and does not anticipate share repurchases in 2025.

Management Comments

• "Our business delivered very strong results in the second quarter, with record net revenues and exceptional growth in operating income and adjusted diluted EPS."
• "These results reflect excellent momentum in our multicategory smoke-free business, with a reacceleration of IQOS adjusted in-market sales growth and ZYN U.S. offtake growth, coupled with combustibles resilience."
• "Given our strong year-to-date performance, we are raising our full-year guidance."

Industry Context

The announcement highlights Philip Morris International's continued successful pivot towards a smoke-free future, with its smoke-free business now contributing significantly to both net revenues and gross profit. While the broader international industry volume for cigarettes and heated tobacco units remained broadly stable or slightly declined, PMI's strong performance in IQOS and ZYN demonstrates its ability to capture market share and drive growth in the evolving nicotine landscape. The reacceleration of IQOS and ZYN growth, coupled with the resilience of combustibles and Marlboro's market share gains, positions PMI favorably within an industry undergoing a significant transformation towards reduced-risk products.

Comparison to Industry Standards

• IQOS strengthened its overall position as the second largest nicotine brand in markets where present, gaining 1.0 percentage point of combined cigarette and HTU industry volumes to reach 9.2% share.
• PMI holds approximately 76% volume share of the global heat-not-burn category, indicating a dominant position.
• In Japan, IQOS HTU adjusted market share increased by 2.3 percentage points to 31.7%, with TEREA and SENTIA further strengthening their #1 and #3 positions despite increased competitive intensity.
• In Europe, IQOS HTU adjusted market share increased by 1.2 percentage points to 10.9%, with offtake share exceeding 20% in key cities of 12 markets.
• Marlboro achieved its highest quarterly market share since the 2008 spin, demonstrating strong brand performance against competitors.
• ZYN reaccelerated its U.S. offtake growth to approximately 36% in June and 26% in Q2 overall as measured by Nielsen, indicating strong competitive performance in the nicotine pouch segment.
• VEEV holds the #1 position in 6 European markets within the closed pods segment, including Greece and Italy, showcasing leadership in specific e-vapor markets.

Legal Proceedings

• Litigation related to tobacco and/or nicotine use and intellectual property.
• Governmental investigations.

Related Party Transactions

• No dividend income from Rothmans, Benson & Hedges Inc. (RBH), a deconsolidated Canadian affiliate.
• PMI continues to report the volume and corresponding royalty revenues of brands sold by RBH for which other PMI subsidiaries are the trademark owner (Next, TEREA, and VEEV).

Stakeholder Impact

• Shareholders are likely to benefit from strong financial results, increased dividend payouts, and a raised full-year guidance, potentially leading to positive share price performance.
• Consumers gain access to an expanding portfolio of smoke-free products, with availability in 97 markets and over 41 million legal-age users, offering alternatives to traditional cigarettes.
• Employees may be impacted by restructuring charges related to manufacturing footprint optimization in Germany, which could involve workforce adjustments.
• Suppliers of raw materials and components for smoke-free products are likely to see continued demand, given the significant capital expenditures planned to support this business segment.

Next Steps

• Broader roll-out of BONDS by IQOS in Indonesia following promising pilot results.
• Continued roll-out of ILUMA i and expansion of the consumables portfolio, including DELIA and new variants of tobacco-free LEVIA, in Europe.
• Reacceleration of commercial activities to further grow the ZYN brand and nicotine pouch category overall.
• Targeting a net debt to adjusted EBITDA ratio of around 2x by the end of 2026.
• Filing of the Quarterly Report on Form 10-Q for the second quarter ended June 30, 2025, in the coming days.

Key Dates

Recommendation

The company delivered exceptional Q2 and H1 2025 results, significantly exceeding prior performance and raising full-year guidance. The strong momentum in the high-growth smoke-free business, particularly IQOS and ZYN, is successfully offsetting declines in traditional combustibles, demonstrating a robust and profitable transition strategy. Market share gains for key smoke-free brands and even Marlboro indicate strong brand power. The increased dividend and commitment to debt reduction further enhance investor confidence. While risks inherent to the industry exist, the current performance and strategic direction suggest significant upside potential for the stock.

Keywords

Philip Morris International, PMI, PM, Earnings, Financial Results, Q2 2025, H1 2025, Smoke-Free Products, IQOS, ZYN, Heated Tobacco Units, HTU, Nicotine Pouches, E-vapor, Combustibles, Cigarettes, Tobacco, Consumer Goods, Dividend, Guidance, EPS, Revenue, Operating Income, Market Share, Corporate Transformation